Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 0.625% 4/0
-
Market price (% of par)
-
97.07%
-
Total 13F principal
-
$397,707,000
-
Principal change
-
-$9,722,784
-
Total reported market value
-
$386,667,091
-
Number of holders
-
39
-
Value change
-
-$9,656,247
-
Number of buys
-
10
-
Number of sells
-
14
Institutional Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q2 2022
As of 30 Jun 2022,
SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 was held by
39 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$397,707,000
in principal (par value) of the bond.
The largest 10 bondholders included
TENOR CAPITAL MANAGEMENT Co., L.P., Radcliffe Capital Management, L.P., Opti Capital Management, LP, DeepCurrents Investment Group LLC, OAKTREE CAPITAL MANAGEMENT LP, JPMORGAN CHASE & CO, Invesco Ltd., AVIVA PLC, CALAMOS ADVISORS LLC, and Sonora Investment Management Group, LLC.
This page lists
39
institutional bondholders reporting positions
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.